A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours

AVE1642 is well tolerated as a single agent and combined with D. The selected dose of AVE1642 combined with D is 6 mg/kg. Promising activity was seen in sarcoma and breast cancer patients.